Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ / shares in Units, € in Millions																	1 Months Ended		3 Months Ended			6 Months Ended			12 Months Ended
	May 19, 2021 USD ($)	May 19, 2021 USD ($)	May 19, 2021 USD ($) program	May 19, 2021 USD ($) research_program	May 19, 2021 USD ($) obligation	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) program $ / shares shares	Feb. 08, 2018 USD ($) program obligation swap_option license	May 02, 2017 USD ($)	May 02, 2017 USD ($)	May 02, 2017 USD ($) program	May 02, 2017 USD ($) obligation	May 02, 2017 USD ($) license	May 02, 2017 USD ($) protein	May 02, 2017 USD ($) lease_agreement	Jan. 31, 2022 USD ($) program	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2022 USD ($) obligation	Jun. 30, 2022 EUR (€) obligation	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 USD ($) obligation program	Dec. 31, 2017 EUR (€) obligation program	Jan. 01, 2019 USD ($)	May 02, 2017 obligation	May 02, 2017 product
Disaggregation of Revenue [Line Items]
Deferred revenues, current portion																			$ 22,863,000			$ 22,863,000			$ 25,116,000
Deferred revenue, net of current portion																			22,063,000			22,063,000			38,403,000
Revenue recognized from contract with customer																			3,700,000			14,300,000
Number of technology licenses \| lease_agreement																5
Total revenue																			3,698,000	$ 3,285,000		14,686,000		$ 18,918,000
Additions to deferred revenue																			0			0
Genentech
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 1,400,000,000	$ 1,400,000,000	$ 1,400,000,000	$ 1,400,000,000	$ 1,400,000,000
Number of initial research programs			2	2
Fee on additional program		10,000,000
Number of optional additional research programs \| program			2
Termination notice period within material breach	90 days
Before first commercial sale	90 days
After first commercial sale	180 days
Number of research programs \| program			4
Remaining performance obligation																			13,200,000			13,200,000
Total revenue																			991,000	0		2,180,000		0
Genentech \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 20,000,000	$ 20,000,000	$ 20,000,000	$ 20,000,000	$ 20,000,000
Deferred revenues, current portion																			7,600,000			7,600,000
Deferred revenue, net of current portion																			5,600,000			5,600,000
Genentech \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term	3 years
Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						$ 6,000,000
Contract with customer asset, after allowance for credit loss						4,000,000
Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation									3
Remaining performance obligation																			17,200,000			17,200,000
Deferred revenues, current portion																			9,300,000			9,300,000
Deferred revenue, net of current portion																			5,200,000			5,200,000
Resale of stock period								60 days
Total revenue																			2,607,000	338,000		2,919,000		704,000
AstraZeneca
Disaggregation of Revenue [Line Items]
Deferred revenue																			700,000			700,000
Research collaboration agreement term										5 years
Remaining performance obligation																			12,000,000			12,000,000
Deferred revenues, current portion																			5,100,000			5,100,000
Deferred revenue, net of current portion																			6,900,000			6,900,000
Revenue recognized from contract with customer																	$ 4,700,000
Resale of stock period							60 days
Total revenue																		$ 13,000,000	(130,000)	2,202,000		4,623,000		16,702,000
Number of discovery programs discontinued \| program																	1
Amortization of capitalized contract costs																						200,000
Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation																											10	10
Remaining performance obligation																			5,300,000			5,300,000
Deferred revenues, current portion																			900,000			900,000
Deferred revenue, net of current portion																			4,400,000			4,400,000
Revenue recognized from contract with customer																						4,900,000
Total revenue																			230,000	$ 745,000		4,964,000		1,512,000
Amortization of capitalized contract costs																						$ 100,000		$ 100,000
Number of programs \| program																											3	3
Number of novel proteins \| program																											1	1
Number of separate performance obligations \| obligation																						3	3
Servier \| Research and Development Services
Disaggregation of Revenue [Line Items]
Number of development programs \| obligation																											2	2
Number of development milestones \| obligation																											3	3
Exclusive Product License Agreement \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue						10,000,000
Revenue, remaining performance obligation, variable consideration amount						352,500,000
Contribution on manufacturing (up to)						$ 4,000,000
Period after effective date agreements may be terminated						9 months
Contract termination advance notice period						60 days
Agreement termination advance notice period if marketing approval obtained						120 days
Agreement termination notice period upon material breach by the Company						180 days
Agreement termination notice period due to non-payment of undisputed amounts						60 days
Contract termination due to material breach, additional notice period if the breach is not susceptible						180 days
Collaborative arrangement, agreement obligation cost						$ 4,000,000
Revenue recognized from contract with customer																									$ 5,700,000
License and Collaboration Agreement \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation					5
License and Collaboration Agreement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| program								3	3
Number of performance obligations \| obligation									6
Period after effective date agreements may be terminated									12 months
Contract termination advance notice period									90 days
Agreement termination advance notice period if marketing approval obtained									180 days
Agreement termination notice period upon material breach by the Company									90 days
Contract termination due to material breach, additional notice period if the breach is not susceptible									90 days
Number of licenses \| license									3
Number of swap options \| swap_option									2
License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation													16
Period after effective date agreements may be terminated										12 months
Contract termination advance notice period										90 days
Agreement termination advance notice period if marketing approval obtained										180 days
Agreement termination notice period upon material breach by the Company										180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible										180 days
Agreement termination notice period upon breach of payment obligations by the Company										30 days
Period of license performance obligation										12 months
Number of novel proteins \| protein															4
License and Collaboration Agreement \| Servier
Disaggregation of Revenue [Line Items]
Number of programs \| program																											5	5
Other arrangement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| program									2
Platform technology license \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation					2
Platform technology license \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation									3
Number of target programs \| program									3
Strategic Partnerships and Other License Agreements \| Servier
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																						$ 3,700,000	€ 3.3
Antibody target swap \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation					2
Antibody target swap \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation									2
Governance committee participation \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation					1
Governance committee participation \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| obligation									1
Upfront Payment \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						$ 10,000,000
Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Deferred revenue									$ 1,200,000,000
Research and development services									4,900,000
Upfront Payment \| Seagen \| License fees
Disaggregation of Revenue [Line Items]
Revenue									$ 30,000,000
Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											$ 45,000,000
Upfront Payment \| Servier \| License fees
Disaggregation of Revenue [Line Items]
Revenue																											$ 32,000,000	€ 30.0
Additional other research services \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											4,700,000
Estimated Development and Manufacturing Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											14,200,000
Milestone Payments \| Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																										$ 4,200,000
Allocable arrangement consideration																					$ 5,000,000
Milestone Payments \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											12,500,000
Estimated Phase 2a Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration											4,700,000
Minimum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products \| product																															2
Minimum \| Strategic Partnerships and Other License Agreements \| Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																											90 days	90 days
Maximum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products																														4	4
Number of research licenses														4		4
Number of programs \| program												2
Maximum \| Strategic Partnerships and Other License Agreements \| Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																											120 days	120 days
Accounting Standards Update 2014-09 \| AstraZeneca
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net										$ 1,600,000	$ 1,600,000	$ 1,600,000	$ 1,600,000	$ 1,600,000	$ 1,600,000	$ 1,600,000			$ 400,000			$ 400,000
Capitalized contract cost in accordance with ASC 340																													$ 1,100,000
Accounting Standards Update 2014-09 \| Servier
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																													$ 500,000
Private placement \| Seagen
Disaggregation of Revenue [Line Items]
Deferred revenue								$ 3,300,000
Shares of stock sold (in shares) \| shares								3,706,174
Shares of stock sold, net consideration								$ 13,000,000
Shares of stock sold, price (USD per share) \| $ / shares								$ 3.51
Fair value of stock (in dollars per share) \| $ / shares								$ 2.61
Private placement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Shares of stock sold (in shares) \| shares							3,584,230
Shares of stock sold, net consideration							$ 10,000,000
Shares of stock sold, price (USD per share) \| $ / shares							$ 2.79
Fair value of stock (in dollars per share) \| $ / shares							$ 2.60